Canada· CA-DIN-02417219
KAZANO
A metformin and alogliptin product containing metformin hydrochloride + alogliptin (alogliptin benzoate), registered in Canada by TAKEDA CANADA INC. The same ATC class is registered in 10 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Metformin and alogliptin is registered in 10 of 19 countries.
Countries holding a registration under ATC A10BD13 (metformin and alogliptin), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 5 of them publish a price we can compare per daily dose
Metformin and alogliptin · ATC A10BD13
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- METFORMIN HYDROCHLORIDE + ALOGLIPTIN (ALOGLIPTIN BENZOATE)
- Manufacturer
- TAKEDA CANADA INC
- Country
- Canada (CA)
- ATC code
- A10BD13
- ATC class
- Metformin and alogliptin
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and alogliptin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and alogliptin · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and alogliptin in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAlogliptin 12.5mg / Metformin 1g tabletsTakeda UK Ltd
- SpainVIPDOMET 12,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULATakeda Pharma A/S
- NetherlandsVipdomet 12,5 mg/ 1000 mg filmomhulde tabletTakeda Pharma A/S
- PolandVipdometTakeda Pharma A/S
- SwedenVipdomet 12,5 mg/1000 mg Filmdragerad tablettTakeda Pharma A/S
- IcelandVipdometTakeda Pharma A/S*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vipdomet
- Liechtenstein · Vipdomet
- Norway · Vipdomet
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6cb75870-2153-4310-a5ae-0a106af2ac7d GET /v1/drugs/6cb75870-2153-4310-a5ae-0a106af2ac7d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02417219",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A10BD13",
"schedule": [
"Prescription"
],
"drug_code": "90185",
"strengths": [
"500 MG",
"12.5 MG"
],
"ahfs_class": null,
"substances": [
"METFORMIN HYDROCHLORIDE",
"ALOGLIPTIN (ALOGLIPTIN BENZOATE)"
],
"product_categorization": null
}See everything about metformin and alogliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.